CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Resveratrol Pill +1 moredrug
Likely dose
Resveratrol Pill 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03384329
NCT03384329Phase 4Completed
CompareCT.gov

Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.

Russian Academy of Medical Sciences·interventional·Posted Dec 27, 2017·Updated Dec 8, 2020

In Brief

A Phase 4 clinical trial evaluating Resveratrol Pill and Placebos for Depression. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Patients with depression (target number - 60) receive resveratrol 500 mg or placebo (1:1) each morning daily for 1 month with primary outcome measures of the score change on depression rating scale HDRS-17 and change in SIRT1 activity in the blood measured 4 times over the study period (before, in the middle, after the intervention, and in 2 week follow up).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesRussia
CollaboratorsRussian Science Foundation

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 27, 2017
Enrollment StartJul 4, 2018
Primary CompletionAug 27, 2019
Study CompletionSep 18, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.5 years ago

Interventions

Resveratrol Pilldrug

Resveratrol 500 mg

Placebosdrug

Placebo Pills